Korean Circulation Journal

  • 제46권6호
  • /
  • Pages.827-833
  • /
  • 2016
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Endocan and Non-Dipping Circadian Pattern in Newly Diagnosed Essential Hypertension

  • Cimen, Tolga (Department of Cardiology, Diskapi Yildirim Beyazit Training and Research Hospital) ;
  • Bilgin, Murat (Department of Cardiology, Diskapi Yildirim Beyazit Training and Research Hospital) ;
  • Akyel, Ahmet (Department of Cardiology, Diskapi Yildirim Beyazit Training and Research Hospital) ;
  • Felekoglu, Mehmet Ali (Department of Cardiology, Diskapi Yildirim Beyazit Training and Research Hospital) ;
  • Nallbani, Ali (Department of Cardiology, Diskapi Yildirim Beyazit Training and Research Hospital) ;
  • Ozdemir, Seyda (Department of Clinical Biochemistry, Diskapi Yildirim Beyazit Training and Research Hospital) ;
  • Erden, Gonul (Department of Clinical Biochemistry, Diskapi Yildirim Beyazit Training and Research Hospital) ;
  • Ozturk, Alpaslan (Department of Clinical Biochemistry, Diskapi Yildirim Beyazit Training and Research Hospital) ;
  • Dogan, Mehmet (Department of Cardiology, Diskapi Yildirim Beyazit Training and Research Hospital) ;
  • Yeter, Ekrem (Department of Cardiology, Diskapi Yildirim Beyazit Training and Research Hospital)
  • 투고 : 2015.12.04
  • 심사 : 2016.04.05
  • 발행 : 2016.11.30
⟨ 이전 논문 다음 논문 ⟩

초록

Background and Objectives: Non-dipper hypertension is frequently accompanied by endothelial dysfunction and activation. Previous studies suggested that endocan may be a novel endothelial dysfunction marker. This study aims to investigate the association between circadian blood pressure (BP) pattern and plasma endocan levels together with high-sensitivity C-reactive protein (hsCRP) in patients with newly diagnosed untreated hypertension. Subjects and Methods: Twenty-four hour ambulatory blood pressure monitoring was recorded in 35 dipper, 35 non-dipper hypertensives and 35 healthy controls. Endocan levels were measured by enzyme-linked immunosorbent assay. Serum levels of hsCRP were also recorded. Results: Despite similar daytime and 24-hour average BP values between dippers and non-dippers, statistically significant high nocturnal BP was accompanied by a non-dipping pattern (Systolic BP: $132{\pm}9$ vs. $147{\pm}11mmHg$; Distolic BP: $80{\pm}7$ vs. $91{\pm}9mmHg$, respectively, p<0.001 for both). Non-dipper patients demonstrated higher endocan levels compared to dippers and normotensives (367 (193-844) pg/mL, 254 (182-512) pg/mL and 237 (141-314) pg/ml, respectively, p<0.001). HsCRP levels were significantly higher in non-dippers than the other groups (p=0.013). In a multivariate logistic regression analysis, endocan (p=0.021) and hsCRP (p=0.044) were independently associated with a non-dipping pattern. Conclusion: Elevated endocan levels were found in non-dipper groups. Endocan and hsCRP were found to be independently associated with a non-dipping pattern. We suggest that elevated levels of endocan in non-dipper hypertensive patients might be associated with a longer duration of exposure to high BP. These results point to the possible future role of endocan in selection of hypertensive patients at higher risk or target organ damage.

키워드

참고문헌

  1. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-6. https://doi.org/10.1001/jama.1996.03530440051036
  2. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-7. https://doi.org/10.1056/NEJM199007053230105
  3. Verdecchia P, Schillaci G, Porcellati C. Dippers versus non-dippers. J Hypertens Suppl 1991;9:S42-4.
  4. Verdecchia P, Schillaci G, Borgioni C, et al. Altered circadian blood pressure profile and prognosis. Blood Press Monit 1997;2:347-52.
  5. Verdecchia P, Schillaci G, Guerrieri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990;81:528-36. https://doi.org/10.1161/01.CIR.81.2.528
  6. Yan B, Peng L, Han D, et al. Blood pressure reverse-dipping is associated with early formation of carotid plaque in senior hypertensive patients. Medicine (Baltimore) 2015;94:e604. https://doi.org/10.1097/MD.0000000000000604
  7. Higashi Y, Nakagawa K, Kimura M, et al. Circadian variation of blood pressure and endothelial function in patients with essential hypertension:a comparison of dippers and non-dippers. J Am Coll Cardiol 2002;40:2039-43. https://doi.org/10.1016/S0735-1097(02)02535-4
  8. Bechard D, Meignin V, Scherpereel A, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000;37:417-25. https://doi.org/10.1159/000025758
  9. Bechard D, Scherpereel A, Hammad H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001;167:3099-106. https://doi.org/10.4049/jimmunol.167.6.3099
  10. Grigoriu BD, Depontieu F, Scherpereel A, et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 2006;12:4575-82. https://doi.org/10.1158/1078-0432.CCR-06-0185
  11. Abid MR, Yi X, Yano K, Shih SC, Aird WC. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 2006;72:136-45. https://doi.org/10.1016/j.mvr.2006.05.010
  12. Balta S, Mikhailidis DP, Demirkol S, et al. Endocan--a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology 2014;65:773-7. https://doi.org/10.1177/0003319713513492
  13. Wang XS, Yang W, Luo T, Wang JM, Jing YY. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers 2015;19:124-7. https://doi.org/10.1089/gtmb.2014.0274
  14. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003
  15. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219. https://doi.org/10.1093/eurheartj/eht151
  16. Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271:20458-64. https://doi.org/10.1074/jbc.271.34.20458
  17. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006;1765:25-37.
  18. Mauno V, Hannu K, Esko K. Proinflammation and Hypertension: A population-based study. Mediators Inflamm 2008;2008:619704.
  19. Celik T, Balta S, Karaman M, et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: Comparative effects of amlodipine and valsartan. Blood Press 2015;24:55-60. https://doi.org/10.3109/08037051.2014.972816
  20. Tadzic R, Mihalj M, Vcev A, Ennen J, Tadzic A, Drenjancevic I. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney Blood Press Res 2013;37:103-15. https://doi.org/10.1159/000350064
  21. Tosu AR, Demir S, Selcuk M, et al. Comparison of inflammatory markers in non-dipper hypertension vs. dipper hypertension and in normotensive individuals: uric acid, C-reactive protein and red blood cell distribution width readings. Postepy Kardiol Interwencyjnej 2014;10:98-103.
  22. von Kanel R, Jain S, Mills PJ, et al. Relation of nocturnal blood pressure dipping to cellular adhesion, inflammation and hemostasis. J Hypertens 2004;22:2087-93. https://doi.org/10.1097/00004872-200411000-00009
  23. Larochelle P. Circadian variation in blood pressure: dipper or nondipper. J Clin Hypertens (Greenwich) 2002;4(4 Suppl 1):3-8. https://doi.org/10.1111/j.1524-6175.2002.01886.x
  24. de la Sierra A, Redon J, Banegas JR, et al. Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension 2009;53:466-72. https://doi.org/10.1161/HYPERTENSIONAHA.108.124008
  25. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002;347:797-805. https://doi.org/10.1056/NEJMoa013410
  26. Fan HQ, Li Y, Thijs L, Hansen TW, et al. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens 2010;28:2036-45. https://doi.org/10.1097/HJH.0b013e32833b49fe
  27. Ozdemir E, Yildirimturk O, Cengiz B, Yurdakul S, Aytekin S. Evaluation of carotid intima-media thickness and aortic elasticity in patients with nondipper hypertension. Echocardiography 2014;31:663-8. https://doi.org/10.1111/echo.12444
  28. Amiya E, Watanabe M, Komuro I. The Relationship between Vascular Function and the Autonomic Nervous System. Ann Vasc Dis 2014;7:109-19. https://doi.org/10.3400/avd.ra.14-00048
  29. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet 1978;1:795-7.
  30. Watson RD, Hamilton CA, Reid JL, Littler WA. Changes in plasma norepinephrine, blood pressure and heart rate during physical activity in hypertensive man. Hypertension 1979;1:341-6. https://doi.org/10.1161/01.HYP.1.4.341

피인용 문헌

  1. Mice overexpressing chromogranin A display hypergranulogenic adrenal glands with attenuated ATP levels contributing to the hypertensive phenotype vol.36, pp.5, 2016, https://doi.org/10.1097/hjh.0000000000001678
  2. The potential role of testosterone in hypertension and target organ damage in hypertensive postmenopausal women vol.14, pp.None, 2016, https://doi.org/10.2147/cia.s195498
  3. The Relationship Between Serum Endocan Level and Aortic Elastic Properties in Patients With Newly Diagnosed Essential Hypertension vol.70, pp.7, 2019, https://doi.org/10.1177/0003319718823625
  4. Serum endocan levels, carotid intima-media thickness and microalbuminuria in patients with newly diagnosed hypertension vol.41, pp.8, 2016, https://doi.org/10.1080/10641963.2019.1652632
  5. The Role of Endocan in Selected Kidney Diseases vol.21, pp.17, 2020, https://doi.org/10.3390/ijms21176119
  6. Endocan: A novel biomarker for risk stratification, prognosis and therapeutic monitoring in human cardiovascular and renal diseases vol.509, pp.None, 2020, https://doi.org/10.1016/j.cca.2020.07.041